Vir Biotechnology, Inc.VIRNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 82% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

82%

Rating Distribution

Strong Buy

00%

Buy

982%

Hold

218%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 102% higher.

Bear Case

$15.00

+102%

Consensus

$15.00

+102%

Bull Case

$15.00

+102%

Price Range11 analysts

Low

Consensus

High

$15.00

Current Target

Current Price

$7.44

Upside to Target

$7.56

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-2.93(7 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+290.17%

EPS—

FY2028

Rev+142.11%

EPS—

FY2029

Rev-15.85%

EPS—

Earnings Surprises

Beat rate:25%(3/12 quarters)

Avg surprise:-17.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 30, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)

Target:$15.00

+150.8%from $5.98

Jul 11, 2025Raymond James

Vir Biotechnology initiated with an Outperform at Raymond James

Target:$12.00

+112.4%from $5.65

Jan 9, 2025Morgan Stanley

Vir Biotechnology upgraded to Overweight from Equal Weight at Morgan Stanley

Target:$20.00

+153.5%from $7.89

Aug 2, 2024Barclays

Vir Biotechnology price target raised to $28 from $27 at Barclays

Target:$28.00

+187.8%from $9.73

Jun 5, 2024Morgan Stanley

Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley

Target:$15.00

+18.5%from $12.66

May 21, 2024Barclays

Barclays Reiterates Overweight Rating on Vir Biotechnology (VIR)

Target:$27.00

+178.6%from $9.69

Feb 21, 2023Goldman Sachs

DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday

Target:$28.38

+10.3%from $25.74

May 6, 2022Needham

Vir Biotechnology (VIR) Stock: $35 Price Target And Buy Rating

Target:$35.00

+60.0%from $21.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance